Outliers in study intended for RSABE [Study As­sess­ment]

posted by Ohlbe – France, 2021-04-26 18:30 (519 d 14:48 ago) – Posting: # 22325
Views: 1,719

Dear Helmut,

» » Subject A - had BLQ (Below limit of Quantification) for all the time points for one of Test treatment and
» » Subject B - had BLQ for all the time points in one of Reference treatment.
» »
» » Can we include Subject A & B for statistical analysis
»
» Well, the statistical model is based on \(\small{\log_{e}}\)-transformed data. You have to exclude them, since \(\small{\log_{e}(0)}\) is undefined (for nitpickers: \(\small{\lim \log_{e}(x\rightarrow 0) = -\infty}\)).

Well, indeed you can't analyse the study without excluding at least that period. NK's study is intended for the US FDA, I don't know how these guys react to such exclusions. In Europe, subject B could be excluded according to the EU BE guideline, but subject A could not as the period with all BLQ was after the test product. EU regulators will tell you that this might be due to your product and you can't exclude the data just because they don't suit you. In such a situation: you're screwed.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,391 posts in 4,685 threads, 1,595 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Wednesday 09:19 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5